On an ex­pan­sion spree, Ger­man man­u­fac­tur­er Sar­to­rius makes $500M+ pur­chase of cell cul­ture me­dia play­er

Over the past year, the Ger­man-based life sci­ence group Sar­to­rius has made sev­er­al moves to grow the com­pa­ny in the cell and gene ther­a­py space, and its lat­est move sees the com­pa­ny con­tin­u­ing that track as it is com­mit­ting to a nine-fig­ure deal to bring UK-based Al­bumedix un­der its wing.

The deal will have Sar­to­rius ac­quir­ing 100% of the com­pa­ny from pri­vate in­vestors for £415 mil­lion, or around $502 mil­lion. Al­bumedix, based in the city of Not­ting­ham, UK, is a man­u­fac­tur­er of al­bu­min-based prod­ucts. Al­bu­min serves as a ma­jor in­gre­di­ent in cell cul­ture me­dia and is used as an an­i­mal-free ad­di­tive in the man­u­fac­tur­ing of vac­cines, cell ther­a­pies and vi­ral ther­a­pies. The trans­ac­tion is ex­pect­ed to close be­fore the end of Q3 of 2022.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN